Arabic Arabic English English French French German German
dark

Protalix BioTherapeutics Announces Closing of Private Note Exchange

Protalix BioTherapeutics, Inc. today announced that it has completed exchanges (the “Exchanges”) of the Company’s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the “2021 Notes”) with institutional note holders of a substantial majority of the 2021 Notes. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Turn Therapeutics Announces Human Trial Data for COVID-19 Early Intervention Candidate

Next Post

New cell phone and smart watch models can interfere with pacemakers and defibrillators

Related Posts
Total
0
Share